Elizabeth Burton, PhD, MBA

Panelists reflect on clinical experience with immunotherapy combinations, the role of biomarkers, and the future of personalized melanoma treatment.

Panelists discuss real-world data comparing outcomes of different immunotherapy combinations for advanced melanoma.

Panelists analyze results from an indirect treatment comparison evaluating different combination immunotherapies in advanced melanoma.

Panelists discuss long-term efficacy and safety outcomes from pivotal studies evaluating dual immune checkpoint inhibition in advanced melanoma.

Panelists discuss current frontline therapeutic strategies for advanced melanoma, highlighting the rationale and evolution of combination immunotherapy approaches.